Matching articles for "cefadroxil"
Issue 1745 · January 5, 2026
Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI

The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients…

Med Lett Drugs Ther. 2026 Jan 5; 68(1745):1-3 doi:10.58347/tml.2026.1745a
The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Issue 1741 · November 10, 2025
Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs

Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):179-80 doi:10.58347/tml.2025.1741b
Orlynvah (Iterum Therapeutics), an oral fixed-dose combination of the thiopenem antibacterial prodrug sulopenem etzadroxil and the renal tubular transport inhibitor probenecid, has been approved by the FDA for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis in women who have limited or no alternative oral antibacterial treatment options. It is the first oral penem-containing product to be approved in the US.
Issue 1674 · April 17, 2023 Free
Treatment of Common Respiratory Tract Infections

Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens.…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):57-62 doi:10.58347/tml.2023.1674a
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Issue 1572 · May 20, 2019
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

The FDA has approved omadacycline ( Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin…

Med Lett Drugs Ther. 2019 May 20; 61(1572):74-7
The FDA has approved omadacycline ( Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Issue 1547 · May 21, 2018
Clarithromycin in Patients with Coronary Artery Disease

The FDA has warned that use of the macrolide antibiotic clarithromycin ( Biaxin , and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.

Med Lett Drugs Ther. 2018 May 21; 60(1547):89-90
The FDA has warned that use of the macrolide antibiotic clarithromycin ( Biaxin , and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
Issue 1532 · October 23, 2017
Drugs for Common Bacterial Infections in Adults

Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can…

Med Lett Drugs Ther. 2017 Oct 23; 59(1532):171-7
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse effects.
Issue 131 · July 1, 2013
Drugs for Bacterial Infections

The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of…

Treat Guidel Med Lett. 2013 Jul; 11(131):65-74
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Issue 1406 · December 24, 2012
Cephalosporins for Patients with Penicillin Allergy

Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.

Med Lett Drugs Ther. 2012 Dec 24; 54(1406):101
Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.
Issue 94 · June 1, 2010
Drugs for Bacterial Infections

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter…

Treat Guidel Med Lett. 2010 Jun; 8(94):43-52
The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 57 · May 1, 2007
Choice of Antibacterial Drugs

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric…

Treat Guidel Med Lett. 2007 May; 5(57):33-50
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Issue 1213 · July 18, 2005
Antibacterial Prophylaxis for Dental, GI and GU Procedures

Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these…

Med Lett Drugs Ther. 2005 Jul 18; 47(1213):59-60
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Issue 19 · March 1, 2004
Choice of Antibacterial Drugs

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the…

Treat Guidel Med Lett. 2004 Mar; 2(19):13-22
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Issue 772 · August 12, 1988
Penicillin Allergy

A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or…

Med Lett Drugs Ther. 1988 Aug 12; 30(772):79-80
A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or some other reaction while taking a penicillin, but maculopapular rashes with ampicillin or amoxicillin, especially in children with infectious mononucleosis, are probably not allergic.
Issue 767 · June 3, 1988
Cefuroxime Axetil

Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the…

Med Lett Drugs Ther. 1988 Jun 3; 30(767):57-9
Cefuroxime axetil ( Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime ( Zinacef ), was recently marketed in the USA. Previously available oral cephalosporins are the first-generation drugs cephalexin ( Keflex ; and others), cephradine ( Anspor ; and others) and cefadroxil ( Duricef ; and others), and the second-generation cefaclor ( Ceclor ); second-generation cephalosporins have more activity against gram-negative bacteria.